We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

SEC Looks Into Dendreon Following FDA Disclosure

Law360 (July 10, 2007, 12:00 AM EDT) -- Biotechnology company Dendreon Corp. said Tuesday that the U.S. Securities and Exchange Commission has opened an informal inquiry into the company's clinical trials for its prostate cancer drug, Provenge.

The inquiry...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.